TC-1698

TC-1698 is a drug that was developed for the treatment of neurological disorders. It is a nicotinic acetylcholine receptor agonist, specifically targeting the α4β2 subtype of this receptor. This subtype is one of the most common in the brain and is implicated in a number of neurological conditions.

History[edit | edit source]

TC-1698 was developed by the pharmaceutical company Targacept. The company was founded in 1997 and has focused on the development of drugs targeting nicotinic acetylcholine receptors. TC-1698 was one of the drugs developed by the company, although it has not yet been approved for use in humans.

Mechanism of Action[edit | edit source]

TC-1698 works by binding to and activating the α4β2 subtype of the nicotinic acetylcholine receptor. This receptor is a type of ion channel, which allows ions to flow across the cell membrane when it is activated. By activating this receptor, TC-1698 can increase the flow of ions across the cell membrane, which can have various effects on the cell's function.

Potential Uses[edit | edit source]

Due to its mechanism of action, TC-1698 has potential uses in the treatment of various neurological disorders. These include Alzheimer's disease, Parkinson's disease, and schizophrenia. However, further research is needed to determine the effectiveness and safety of TC-1698 in treating these conditions.

Clinical Trials[edit | edit source]

As of now, TC-1698 has undergone preclinical trials, which have shown promising results. However, it has not yet undergone clinical trials in humans. Therefore, it is not currently available for use in the treatment of any condition.